KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gilead Sciences (GILD) EBT (2016 - 2025)

Historic EBT for Gilead Sciences (GILD) over the last 17 years, with Q3 2025 value amounting to $3.6 billion.

  • Gilead Sciences' EBT rose 28085.77% to $3.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $9.9 billion, marking a year-over-year increase of 551704.55%. This contributed to the annual value of $690.0 million for FY2024, which is 8994.02% down from last year.
  • Latest data reveals that Gilead Sciences reported EBT of $3.6 billion as of Q3 2025, which was up 28085.77% from $2.4 billion recorded in Q2 2025.
  • Gilead Sciences' EBT's 5-year high stood at $3.6 billion during Q3 2025, with a 5-year trough of -$4.5 billion in Q1 2024.
  • Moreover, its 5-year median value for EBT was $1.8 billion (2021), whereas its average is $1.5 billion.
  • Per our database at Business Quant, Gilead Sciences' EBT surged by 95526.32% in 2023 and then plummeted by 44507.69% in 2024.
  • Quarter analysis of 5 years shows Gilead Sciences' EBT stood at $759.0 million in 2021, then soared by 167.59% to $2.0 billion in 2022, then dropped by 18.61% to $1.7 billion in 2023, then skyrocketed by 31.09% to $2.2 billion in 2024, then surged by 68.02% to $3.6 billion in 2025.
  • Its last three reported values are $3.6 billion in Q3 2025, $2.4 billion for Q2 2025, and $1.6 billion during Q1 2025.